Quoin Pharmaceuticals, Ltd. (QNRX)
| Previous Close | 0.7801 |
| Open | 0.7876 |
| Bid | 0.7303 x 100 |
| Ask | 0.7705 x 100 |
| Day's Range | 0.7352 - 0.8000 |
| 52 Week Range | 0.6030 - 12.0000 |
| Volume | |
| Avg. Volume | 653,103 |
| Market Cap | 2.746M |
| Beta (5Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.6400 |
| Earnings Date | May 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.80 |
GlobeNewswireQuoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quarter 2024 financial results before the market opens on Thursday, May 9, 2024. The announcement will provide an operational update regarding the company’s achievements during the quarter, and will detail financial highlights. About Qu
Insider MonkeyQuoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript March 14, 2024 Quoin Pharmaceuticals, Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Quoin Pharmaceuticals Fourth Quarter Financial Results and Business Update Conference Call. […]
- GlobeNewswire
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpoints Eligibility age for enrollment into both studies has been lowered to fourteen years and older No safety concerns have been observed to date in either ongoing clinical study Quoin expects its cash runway will extend into the second half of 2025 following $6.5 million offering on March 5th C
